Literature DB >> 9640371

Leucoderma treated by transplantation of a basal cell layer enriched suspension.

M J Olsson1, L Juhlin.   

Abstract

The aim of this study was to test the usefulness of a melanocyte-enriched cell suspension for the treatment of leucoderma. After removal of a superficial (4-30 cm2) skin sample, the cells were mechanically separated in a trypsin-EDTA solution, centrifuged and washed in a melanocyte medium. The melanocyte-enriched epidermal cell suspension devoid of stratum corneum and stratum granulosum was then applied to the dermabraded depigmented skin. The 26 patients treated had piebaldism (three), vitiligo vulgaris (17), segmental vitiligo (three), halo naevi (one), naevus depigmentosus (one) and chemical leucoderma (one). In patients with widespread piebaldism we found that by diluting the cell suspension the recipient area could be increased to up to 10 times the size of the donor area with the same good results as without or with less dilution. In patients with vitiligo areas of between 50 and 90 cm2, the recipient areas were increased three- to fivefold in the donor area. Patients with piebaldism, segmental vitiligo and halo naevi healed completely, as did most patients with vitiligo. In naevus depigmentosus no effect was seen. Our new method for treatment of leucoderma has the advantage that cell culture is not needed and that it is more suitable than epidermal sheet grafts when several small areas are to be treated.

Entities:  

Mesh:

Year:  1998        PMID: 9640371     DOI: 10.1046/j.1365-2133.1998.02177.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  19 in total

Review 1.  Hypopigmentary skin disorders: current treatment options and future directions.

Authors:  Anke Hartmann; Eva-B Bröcker; Jürgen C Becker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Non-cultured melanocyte/keratinocyte transplantation for the treatment of stable vitiligo on the face: report of two cases.

Authors:  Mariana Gontijo Ramos; Daniel Gontijo Ramos; Gabriel Gontijo; Camila Gontijo Ramos; Tania Nely Rocha; Rafael Henrique Rocha
Journal:  An Bras Dermatol       Date:  2013 Sep-Oct       Impact factor: 1.896

Review 3.  Hair Follicle as a Source of Pigment-Producing Cells for Treatment of Vitiligo: An Alternative to Epidermis?

Authors:  Mahshid Ghasemi; Amir Bajouri; Saeed Shafiiyan; Nasser Aghdami
Journal:  Tissue Eng Regen Med       Date:  2020-10-09       Impact factor: 4.169

Review 4.  Cell therapy in dermatology.

Authors:  Gabriela Petrof; Alya Abdul-Wahab; John A McGrath
Journal:  Cold Spring Harb Perspect Med       Date:  2014-06-02       Impact factor: 6.915

5.  A comparative study of efficacy of cultured versus non cultured melanocyte transfer in the management of stable vitiligo.

Authors:  Rajesh Verma; R S Grewal; Manas Chatterjee; Vijendran Pragasam; Biju Vasudevan; Debdeep Mitra
Journal:  Med J Armed Forces India       Date:  2013-11-20

6.  Innovative Technique for Securing Autologous Melanocyte-keratinocyte Cell Transplant (MKCT) Suspension in Stable Vitiligo.

Authors:  Sharad Dattatray Mutalik; Yashashree Dhaval Rasal
Journal:  J Cutan Aesthet Surg       Date:  2021 Jan-Mar

7.  Autologous Non-cultured Basal Cell-Enriched Epidermal Cell Suspension Transplantation in Vitiligo: Indian Experience.

Authors:  Munish Paul
Journal:  J Cutan Aesthet Surg       Date:  2011-01

8.  Nevus depigmentosus treated by melanocyte-keratinocyte transplantation.

Authors:  Sanjeev V Mulekar; Ahmed Al Issa; Abdullah Al Eisa
Journal:  J Cutan Aesthet Surg       Date:  2011-01

9.  Cellular grafts in management of leucoderma.

Authors:  Venkataram Mysore; T Salim
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

10.  Donor to recipient ratios in the surgical treatment of vitiligo and piebaldism: a systematic review.

Authors:  V S Narayan; L L C van den Bol; N van Geel; M W Bekkenk; R M Luiten; A Wolkerstorfer
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-02-12       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.